254 related articles for article (PubMed ID: 21233488)
1. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.
Good CH; Hoffman AF; Hoffer BJ; Chefer VI; Shippenberg TS; Bäckman CM; Larsson NG; Olson L; Gellhaar S; Galter D; Lupica CR
FASEB J; 2011 Apr; 25(4):1333-44. PubMed ID: 21233488
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
[TBL] [Abstract][Full Text] [Related]
3. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
[TBL] [Abstract][Full Text] [Related]
4. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
Ekstrand MI; Galter D
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
[TBL] [Abstract][Full Text] [Related]
5. Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
Langley MR; Ghaisas S; Palanisamy BN; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Exp Neurol; 2021 Jul; 341():113716. PubMed ID: 33839143
[TBL] [Abstract][Full Text] [Related]
6. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease.
Fifel K; Cooper HM
Neurobiol Dis; 2014 Nov; 71():359-69. PubMed ID: 25171792
[TBL] [Abstract][Full Text] [Related]
7. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
[TBL] [Abstract][Full Text] [Related]
8. Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson's disease.
Lai JH; Chen KY; Wu JC; Olson L; Brené S; Huang CZ; Chen YH; Kang SJ; Ma KH; Hoffer BJ; Hsieh TH; Chiang YH
Brain Res; 2019 Oct; 1720():146301. PubMed ID: 31226324
[TBL] [Abstract][Full Text] [Related]
9. Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
Beckstead MJ; Howell RD
Exp Neurol; 2021 Jul; 341():113707. PubMed ID: 33753138
[TBL] [Abstract][Full Text] [Related]
10. Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.
Farrand AQ; Gregory RA; Bäckman CM; Helke KL; Boger HA
Brain Res; 2016 Nov; 1651():88-94. PubMed ID: 27659966
[TBL] [Abstract][Full Text] [Related]
11. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.
Galter D; Pernold K; Yoshitake T; Lindqvist E; Hoffer B; Kehr J; Larsson NG; Olson L
Genes Brain Behav; 2010 Mar; 9(2):173-81. PubMed ID: 20002202
[TBL] [Abstract][Full Text] [Related]
12. Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's Disease.
Cong L; Muir ER; Chen C; Qian Y; Liu J; Biju KC; Clark RA; Li S; Duong TQ
PLoS One; 2016; 11(3):e0151884. PubMed ID: 27003179
[TBL] [Abstract][Full Text] [Related]
13. Transgenic rodent models of Parkinson's disease.
Harvey BK; Wang Y; Hoffer BJ
Acta Neurochir Suppl; 2008; 101():89-92. PubMed ID: 18642640
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
Ay M; Luo J; Langley M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
J Neurochem; 2017 Jun; 141(5):766-782. PubMed ID: 28376279
[TBL] [Abstract][Full Text] [Related]
15. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
[TBL] [Abstract][Full Text] [Related]
16. Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.
Lynch WB; Tschumi CW; Sharpe AL; Branch SY; Chen C; Ge G; Li S; Beckstead MJ
Mov Disord; 2018 Dec; 33(12):1928-1937. PubMed ID: 30440089
[TBL] [Abstract][Full Text] [Related]
17. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
Langley M; Ghosh A; Charli A; Sarkar S; Ay M; Luo J; Zielonka J; Brenza T; Bennett B; Jin H; Ghaisas S; Schlichtmann B; Kim D; Anantharam V; Kanthasamy A; Narasimhan B; Kalyanaraman B; Kanthasamy AG
Antioxid Redox Signal; 2017 Nov; 27(14):1048-1066. PubMed ID: 28375739
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.
Brimblecombe KR; Connor-Robson N; Bataille CJR; Roberts BM; Gracie C; O'Connor B; Te Water Naude R; Karthik G; Russell AJ; Wade-Martins R; Cragg SJ
Eur J Neurosci; 2024 Mar; 59(6):1242-1259. PubMed ID: 37941514
[TBL] [Abstract][Full Text] [Related]
20. Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease.
Li X; Redus L; Chen C; Martinez PA; Strong R; Li S; O'Connor JC
PLoS One; 2013; 8(8):e71341. PubMed ID: 23977020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
